COMPARATIVE HPLC ANALYSIS OF SIPROFLOKS-АК 250 MG AND 500 MG DOSAGE FORMS
DOI:
https://doi.org/10.55640/Keywords:
HPLC, Ciprofloxacin, SIPROFLOKS-АК, quantitative analysis, dosage comparisonAbstract
The present study aimed to perform a comparative quantitative analysis of SIPROFLOKS-АК tablets in 250 mg and 500 mg dosage forms using high-performance liquid chromatography (HPLC). The analysis focused on evaluating the uniformity and actual content of ciprofloxacin in both dosage strengths. A reverse-phase HPLC method with UV detection at 278 nm was developed and validated. Results indicated that both dosage forms comply with pharmacopeial standards, with slight variations in content uniformity observed. This study confirms the reliability of the HPLC method for routine quality control of SIPROFLOKS-АК produced by «AS-KAM PHARMA».
Downloads
References
1.ICH Q2(R1), “Validation of Analytical Procedures: Text and Methodology,” International Council for Harmonisation, 2005.
2.European Pharmacopoeia, 11th Edition, “Ciprofloxacin Tablets,” 2022.
3.Shimadzu Corporation, HPLC Principles and Applications, 2018.
4.Sweetman, S.C., Martindale: The Complete Drug Reference, 39th Edition, Pharmaceutical Press, 2020.
5.Patel, M., et al., “HPLC Analysis of Ciprofloxacin in Pharmaceutical Dosage Forms,” Journal of Pharmaceutical Analysis, 2017;7(5): 310–316.
6.Yuqori samarali suyuqlik xromatografiyasi (HPLC) yordamida dekserich suyuq ekstraktidagi rutin kontsentratsiyasini tahlil qilish
M Axmatoxunova, A Shokirov - Journal of Integrated Education and Research, 2024
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India